IFN—α治疗白塞病葡萄膜炎的新进展

Progress in IFN-α treatment of uveitis patients with Behcet＇s disease

白塞病（BD）是一种累及多系统、多器官的慢性、复发性、全身性疾病。由BD引起的葡萄膜炎是我国常见葡萄膜炎中重要的致盲类型，目前尚无根治方法。IFN-α是一种具有多种生物学效应的细胞因子，具有较强的免疫双向调节作用。近年来IFN-α被尝试用于治疗伴有眼部葡萄膜炎的BD患者，临床研究发现IFN-α治疗能够有效控制BD葡萄膜炎病情的发展，降低复发频率，对于反复发作、常规激素和免疫抑制剂治疗无效的BD葡萄膜炎患者，不失为一种较好的治疗选择；但其作用的机制、长期的治疗效果，仍需进一步的临床研究观察。

Behcet disease （BD） is a chronic, recrudescent, systemic disease which involves muhi-organ. Uveitis caused by BD is a common type of uveitis inducing blindness in China. There is no radical cure for this kind of uveitis at present. IFN-α is a kind of cytokine which has multiple biological effects. It has a dual immunomodulatory activity, and has been applied to uveitis patients with BD disease in recent years. Clinical investigation has found IFN-α treatment is effective in controlling the progress of BD uveitis, reducing the frequency of disease recurrence. For the BD uveitis patients who are resistance to normal steroids and immunosuppressive drugs, IFN-α treatment will bring new hope. Otherwise, the mechanism and long-term effect of IFN-α treatment need more clinical studies.